Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small cell lung cancer.

G E Goodman1, R B Livingston

  • 1Swedish Hospital Medical Center, Tumor Institute, Seattle, Washington.

Current Problems in Cancer
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Small cell lung cancer (SCLC) therapy has improved significantly, with median survival now 1-2 years due to chemotherapy and radiotherapy. This progress offers hope for a cure in some patients with limited disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Breast cancer research and treatment·2016
Same author

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.

The pharmacogenomics journal·2013
Same author

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Stimulation of area 13 and skin temperature changes following its ablation.

Federation proceedings·2010
Same author

Ablation of area 13 in primates.

Federation proceedings·2010
Same author

Pathology in suddenly decompressed rats.

Federation proceedings·2010
Same journal

Clinical impact of a single time-point protocol paired FDG-PET and radioactive iodine scan for comprehensive disease assessment in differentiated thyroid cancer.

Current problems in cancer·2026
Same journal

Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database.

Current problems in cancer·2026
Same journal

Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer.

Current problems in cancer·2026
Same journal

Artificial intelligence, omics, and biomarkers: Redefining lung cancer early detection.

Current problems in cancer·2026
Same journal

Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

Current problems in cancer·2026
Same journal

Advancements and perspectives of neoadjuvant immunotherapy in resectable non-small cell lung cancer.

Current problems in cancer·2026
See all related articles

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Research

Background:

  • Small cell lung cancer (SCLC) accounts for 20% of lung cancer cases.
  • SCLC exhibits distinct biologic behavior and therapeutic responsiveness compared to other lung cancer subtypes.
  • Despite advances, overall lung cancer survival rates remain below 10%.

Purpose of the Study:

  • To describe the unique characteristics of SCLC.
  • To provide an overview of current SCLC clinical management and treatment strategies.
  • To highlight therapeutic progress in SCLC.

Main Methods:

  • Review of clinical trials evaluating chemotherapy and radiotherapy combinations for SCLC.
  • Analysis of SCLC's distinct biologic behavior, paraneoplastic syndromes, and early dissemination.

Related Experiment Videos

  • Comparison of SCLC to other histological lung cancer subtypes.

    • Main Results:

    • Median survival for SCLC has increased from 3 months in the 1960s to 1-2 years with combination therapy.
    • Approximately 10% of limited-stage SCLC patients survive longer than 2 years, indicating curative potential.
    • SCLC's sensitivity to chemotherapy and radiation has driven numerous clinical trials.

    Conclusions:

    • Significant therapeutic advancements have been made in SCLC management.
    • Combination chemotherapy and radiotherapy have markedly improved SCLC patient survival.
    • Further research into SCLC's unique biology is crucial for continued treatment optimization.